Current treatments in nonalcoholic steatohepatitis

Current Treatment Options in Gastroenterology

Volumn 10, Issue 6, 2007, Pages 425-434

  Torres, Dawn M ^b   Harrison, Stephen A ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ASCORBIC ACID; BETAINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER PROTECTIVE AGENT; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

BONE ATROPHY; CARDIOVASCULAR DISEASE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DIET; DISEASE COURSE; EXERCISE; FATTY LIVER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; METABOLIC SYNDROME X; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; UNITED STATES; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 37349004137     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0042-y     Document Type: Review

References (67)

1. Beymer C, Kowdley KV, Larson AA, et al.: Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 2003, 138:1240-1244.
2. Machado M, Marques-Vidal P, Cortez-Pinto H: Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006, 45:600-606.
3. Wanless IR, Lentz JS: Fatty liver steatosis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 11:74-80.
4. Harrison SA, Day CP: Benefits of lifestyle modification in NAFLD. Gut 2007, In press.
5. Harrison SA, Neuschwander-Tetri BA: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 2004, 8:861-879.
6. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ: The evolving role of leptin and adiponectinin chronic liver disease. Am J Gastroenterol 2006, 101:1-12.
7. Pessayre D, Berson A, Fromenty B, Mansouri A: Mitochondria in steatohepatitis. Semin Liver Dis 2001, 21:57-69.
8. Harrison SA, Torgerson S, Hayashi PH: The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003, 98:2042-2047.
9. Adams LA, Sanderson S, Lindor KD, Angulo P: The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005, 42:132-138.
10. Adams LA, Lymp JF, Sauver J, et al.: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
11. Capristo E, Miele L, Forgione A, et al.: Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH). Eur Rev Med Pharmacol Sci 2005, 9:265-268.
12. Sato F, Tamura Y, Watada H, et al.: Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrin Metab 2007, 92:3325-3329.
13. Fisler JS, Drenick EJ: Starvation and semistarvation diets in the management of obesity. Annu Rev Nutr 1987, 7:465-484.
14. Palmer M, Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990, 99:1408-1413.
15. Anderson T, Gluud C, Franzmann MB, Christoffersen P: Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991, 12:224-229.
16. Okita M, Hayashi M, Sasagawa T, et al.: Effect of moderately energy-restricted diet on obese patients with fatty liver. Nutrition 2001, 17:542-547.
17. Thomas EL, Brynes AE, Hamilton G, et al.: Effect of nutritional counseling on hepatic, muscle, and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 2006, 12:5813-5819.
18. Wang RT, Koretz RL, Yee HF: Is weight reduction an effective therapy for nonalcoholic fatty liver? A systemic review. Am J Med 2003, 114:554-559.
19. Huang MA, Greenson JK, Chao C, et al.: One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005, 100:1072-1081.
20. Musso G, Gambino R, De Michieli F, et al.: Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37:909-916.
21. Cortez-Pinto H, Jesus L, Barros H, et al.: How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 2006, 25:816-823.
22. Sekiya M, Yahagi N, Matsuzaka T, et al.: Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-I suppression. Hepatology 2003, 38:1529-1539.
23. El-Badry AM, Moritz W, Contaldo C, et al.: Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. Hepatology 2007, 45:841-845.
24. Capanni M, Calella F, Biagini MR, et al.: Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006, 23:1143-1151.
25. Spadaro L, Magliocco O, Spampinato D, et al.: 738 omega-3 polyunsaturated fatty acids: a pilot trial in non-alcoholic fatty liver disease. J Hepatol 2006, 44:S264.
26. Paniagua JA, Gallego de la Sacristana A, Romero I, et al.: Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care 2007, 30:1717-1723.
27. Le KA, Tappy L, D'Alessio DA: Mitochondrial dysfunction and insulin resistance: a matter of lifestyle? Curr Opin Clin Nutr Metab Care 2007, 10:494-497.
28. Yancy WS, Olsen MK, Guyton JR, et al.: A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia. Ann Intern Med 2004, 140:769-777.
29. Tendler D, Lin S, Yancy WS, et al.: The effect of low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007, 52:589-593.
30. Petersen KF, Dufour S, Belfroy D, et al.: Reversal of nonalcoholic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005, 54:603-608.
31. Westerbacka J, Lammi K, Hakkinen AM, et al.: Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005, 90:2804-2809.
32. Suzuki A, Lindor K, St Saver J, et al.: Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005, 43:1060-1066.
33. Hickman IJ, Jonsson JR, Prins JB, et al.: Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004, 53:413-419.
34. Harrison SA, Fincke C, Helinski D, et al.: A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004, 20:623-628.
35. Assy N, Hussein O, Abassi Z: Weight loss induced by orlistat reverses fatty infiltration and improved hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 2007, 56:443-444.
36. Zeiber-Sagi S, Kessler A, Brazowsky E, et al.: A doubleblind randomized placebo-controlled trial of orlistat for treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006, 4:639-644.
37. Harrison SA, Brunt EM, Fecht WJ, et al.: Orlistat in the treatment of overweight patients with nonalcoholic steatohepatitis (NASH): a multi-centered, randomized, prospective trial. Gastroenterology 2007, 4(Suppl 2):T1059.
38. Marubbio AT, Buchwald H, Schwartz MZ, Varco R: Hepatic lesions of central pericellular fibrosis in morbid obesity, and after jejunoileal bypass. Am J Clin Pathol 1976, 66:684-691.
39. Campbell JM, Hunk TK, Karam JH, Forsham PH: Jejunoileal bypass as a treatment of morbid obesity. Arch Intern Med 1977, 137:602-610.
40. Kral JG, Thung SN, Biron S, et al.: Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004, 135:48-58.
41. Dixon JB, Bhathal PS, Hughes NR, et al.: Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004, 39:1647-1654.
42. Klein S, Mittendorfer B, Eagon C, et al.: Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006, 130:1564-1572.
43. Barker KB, Palekar NA, Bowers SP, et al.: Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006, 101:368-373.
44. Furuya CK, de Oliveira CP, de Mello ES, et al.: Effects of bariatric surgery ou nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 2007, 22:510-514.
45. Lutchman G, Promrat K, Kleiner DE, et al.: Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histologic improvement. Clin Gastroenterol Hepatol 2006, 4:1048-1052.
46. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al.: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38:1008-1017.
47. Belfort R, Harrison SA, Brown K, et al.: A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:15-25.
48. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
49. Lin HZ, Yang SQ, Chuckaree C, et al.: Metformin reverses fatty liver disease in obese leptin-deficient mice. Nat Med 2000, 6:998-1003.
50. Marchensini G, Bianchi G, Tomassetti S, et al.: Metformin in non-alcoholic steatohepatitis. Lancet 348, 2001:893-894.
51. Uygun A, Kadayifci A, Isik AT, et al.: Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004, 19:537-544.
52. Bugianesi E, Gentilcore E, Manini R, et al.: A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082-1090.
53. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al.: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53:2169-2176.
54. Harrison SA, Torgerson S, Hayashi P, et al.: Vitamin E and C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98:2485-2490.
55. Yakaryilmaz F, Guliter S, Saras B, et al.: Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J 2007, 37:229-235.
56. Federico A, Trappoliere M, Tuccillo C, et al.: A new silybin-vitamin E-phopholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut 2006, 55:901-902.
57. Abdelmalek MF, Angulo P, Jorgenssen R, et al.: Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001, 96:2711-2717.
58. Pamuk GE, Sonsuz A: N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2003, 18:220-221.
59. Lindor KD, Kowdley KV, Heathcote EJ, et al.: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770-778.
60. Adams LA, Zeine CO, Angulo P, et al.: A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99:2365-2368.
61. Satapathy SK, Sakhuja P, Malhotra V, et al.: Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steato-hepatitis. J Gastroenterol Hepatol 2006, 22:634-638.
62. Browning JD: Statins and hepatic steatosis: perspectives from the Dallas heart study. Hepatology 2006, 44:466-471.
63. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, et al.: A pilot study of atorvastatin treatment in dyslipdemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006, 23:1643-1647.
64. Ekstedt M, Franzen LE, Mathiesen UL, et al.: Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007, 47:135-141.
65. Hirose A, Ono M, Saibara T, et al.: Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007, 45:1375-1381.
66. Yokohama S, Yoneda M, Haneda M: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222-1225.
67. Yokohama S, Tokusashi Y, Nakamura K, et al.: Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006, 12:322-326.